Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
- 27 April 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 21 (6), 763-775
- https://doi.org/10.1016/s1470-2045(20)30112-1
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor XenograftsClinical Cancer Research, 2014
- US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 StatusJNCI Journal of the National Cancer Institute, 2014
- Resistance to human epidermal growth factor receptor type 2-targeted therapiesEuropean Journal of Cancer, 2014
- A systematic review of dual targeting in HER2-positive breast cancerCancer Treatment Reviews, 2014
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast CancerJournal of Clinical Oncology, 2009
- Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM StudyJournal of Clinical Oncology, 2009
- Lapatinib plus Capecitabine for HER2-Positive Advanced Breast CancerThe New England Journal of Medicine, 2006
- Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study GroupJournal of Clinical Oncology, 2005
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2The New England Journal of Medicine, 2001
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993